中和
生物
病毒学
金标准(测试)
病毒
潜伏期
严重急性呼吸综合征冠状病毒2型(SARS-CoV-2)
中和抗体
抗体
2019年冠状病毒病(COVID-19)
病毒载量
孵化
免疫学
传染病(医学专业)
医学
内科学
生物化学
疾病
作者
Alessandro Manenti,Eleonora Molesti,Marta Maggetti,Alessandro Torelli,Giulia Lapini,Emanuele Montomoli
标识
DOI:10.1016/j.jviromet.2021.114261
摘要
The neutralization assays are considered the gold-standard being capable of evaluating and detecting, functional antibodies. To date, many different protocols exist for micro-neutralization (MN) assay which varies in several steps: cell number and seeding conditions, virus amount used in the infection step, virus-serum-cells incubation time and read out. The aim of the present preliminary study was to carry out SARS-CoV-2 wild type MN assay in order to investigate which optimal tissue culture infective dose 50 (TCID50) infective dose in use is the most adequate choice for implementation in terms of reproducibility, standardization possibilities and comparability of results. Therefore, we assessed the MN by using two viral infective doses: the “standard” dose of 100 TCID50/well and a reduced dose of 25 TCID50/well. The results obtained, yielded by MN on using the lower infective dose (25 TCID50), were higher respect to those obtained with the standard infective dose. This suggests that the lower dose can potentially have a positive impact on the detection and estimation of real amount of neutralizing antibodies present in a given sample, showing higher sensitivity maintaining high specificity.
科研通智能强力驱动
Strongly Powered by AbleSci AI